How is ASAH1-related sphingolipidosis diagnosed?

Information about diagnosis is currently limited for this condition.

Are there treatments for ASAH1-related sphingolipidosis?

Information about treatment is currently limited for this condition.

What complications can arise from ASAH1-related sphingolipidosis?

Complications from ASAH1-related sphingolipidosis can vary widely because the condition affects people differently. Some may experience severe symptoms associated with Farber disease or spinal muscular atrophy with progressive myoclonic epilepsy. These complications can impact mobility, muscle function, and overall health, making it important to monitor changes closely.

How does ASAH1-related sphingolipidosis affect daily life?

Living with ASAH1-related sphingolipidosis can be challenging due to the potential for varying symptoms and complications. Daily activities may be impacted depending on the severity of the condition, especially if mobility or muscle function is affected. Families may need to adapt routines and seek support to manage these challenges effectively.

What is the life expectancy for someone with ASAH1-related sphingolipidosis?

Information about life expectancy for individuals with ASAH1-related sphingolipidosis is currently limited. The severity of symptoms and complications can vary greatly, which makes it difficult to predict outcomes. It's important for families to work closely with healthcare providers to understand the specific situation and what it may mean for their loved one.

Should families consider genetic counseling for ASAH1-related sphingolipidosis?

Yes, families may want to consider genetic counseling for ASAH1-related sphingolipidosis. Since this condition is caused by changes in the ASAH1 gene, understanding the genetic aspects can help families make informed decisions about family planning and the risk of passing the condition to future generations. A genetic counselor can provide valuable information and support.

Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

ASAH1-related sphingolipidosis - Clinical Profile, Genes & Research | Kisho | Kisho

Rare Disease

ASAH1-related sphingolipidosis

MONDO:0100524

Also known as:ASAH1-related disordersacid ceramidase deficiency

Overview

A spectrum of disorders caused by variation(s) in the ASAH1 genel this spectrum includes Farber disease and spinal muscular atrophy with progressive myoclonic epilepsy. The ASAH1 gene encodes the lysosomal hydrolase that breaks down the bioactive lipid, ceramide.

ResearchLimited published research (9 articles)

Clinical Presentation

Built from Human Phenotype Ontology (HPO) phenotype annotations and GeneReviews clinical descriptions. Features represent findings documented across known cases — not an exhaustive list of possible symptoms.

No HPO annotations are available for this condition.

GeneReviews

Clinical Guidance

ASAH1-related disorders comprise a spectrum that ranges from Farber disease (FD) to spinal muscular atrophy (SMA) with or without epilepsy. ASAH1-related disorders vary in the age of onset of manifestations, the systems affected, and severity and progression of the disease. While Farber disease has been recognized clinically and diagnosed for decades based on enzyme analysis , the recognition of ASAH1-related SMA and associated findings is a recent discovery based on the use of genomic testing; thus, the understanding of the latter ASAH1-related phenotype is still evolving.

Diagnosis

Drawn from GeneReviews diagnostic guidelines, newborn screening panel status (RUSP), and ClinGen gene-disease validity classifications. Reflects current clinical evidence and consensus where available.

GeneReviews

Diagnostic Criteria

Suggestive Findings

The following phenotypes of the ASAH1-related disorders should be suspected based on the following age-related clinical and associated findings. Farber disease (FD) should be strongly suspected in a neonate or toddler with the following:

Clinical findings

Subcutaneous nodules located at pressure points and joints
Swollen, painful joints with progressive limitation of range of motion resulting in contractures

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

No approved treatments are currently available for ASAH1-related sphingolipidosis. The disease remains an area of unmet medical need.

GeneReviews

Management Guidelines

Evaluations Following Initial Diagnosis To establish the extent of disease and needs in an individual diagnosed with an ASAH1-related disorder, the evaluations summarized in and (if not performed as part of the evaluation that led to the diagnosis) are recommended. Table 3a. Recommended Evaluations Following Initial Diagnosis of an ASAH1-Related Disorder: Farber Disease

Prognosis

Based on GeneReviews surveillance recommendations, HPO phenotype frequency and severity annotations, and published prevalence estimates from Orphanet and OMIM.

GeneReviews

Surveillance Guidelines

No guidelines have been published for the surveillance of ASAH1-related disorder. Table 5a. Recommended Surveillance for Individuals with ASAH1-Related Disorder: Farber Disease

System/Concern

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

No clinical trials have been registered for ASAH1-related sphingolipidosis.

9 publications have been identified in PubMed for ASAH1-related sphingolipidosis. Research spans Basic Science / Preclinical (44%), Review / Meta-Analysis (22%), and Clinical Trial Publication (11%).

Recent Publications

Taha HB (2026). [PMID: 41627451](https://pubmed.ncbi.nlm.nih.gov/41627451/). *Journal of molecular medicine (Berlin, Germany)*. [Review / Meta-Analysis]
Lucas NCC (2025). [PMID: 40778235](https://pubmed.ncbi.nlm.nih.gov/40778235/). *JIMD reports*. [Clinical Trial Publication]
Markaki SP (2025). [PMID: 41511290](https://pubmed.ncbi.nlm.nih.gov/41511290/). *Cells*. [Basic Science / Preclinical]
Han J (2025). [PMID: 40766362](https://pubmed.ncbi.nlm.nih.gov/40766362/). *bioRxiv : the preprint server for biology*. [Basic Science / Preclinical]
Kleynerman A (2025). [PMID: 39665198](https://pubmed.ncbi.nlm.nih.gov/39665198/). *American journal of physiology. Heart and circulatory physiology*. [Basic Science / Preclinical]

Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 2:35 PM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

Questions for Your Care Team

→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

FAQ

Frequently Asked Questions

Common questions about ASAH1-related sphingolipidosis

ASAH1-related sphingolipidosis is a spectrum of disorders linked to changes in the ASAH1 gene. This gene makes an enzyme known as acid ceramidase, which helps break down a fat-like substance called ceramide. Problems with this enzyme can lead to issues in how the body handles ceramide, causing a range of disorders. This spectrum includes conditions such as Farber disease and spinal muscular atrophy with progressive myoclonic epilepsy. The severity and symptoms can vary among people with these disorders. The complexity of the condition is rooted in genetic differences affecting enzyme function.

Information about symptoms is currently limited for this condition.

This condition is caused by variations in the ASAH1 gene, which encodes acid ceramidase, an enzyme needed to break down the lipid ceramide. When the gene does not function correctly due to genetic changes, it can lead to a build-up of ceramide and result in disorders such as Farber disease and spinal muscular atrophy with progressive myoclonic epilepsy. Associated genes include ASAH1.

← Back to All Diseases

GeneReviews

Differential Diagnosis

Table 2. Inherited Disorders to Consider in the Differential Diagnosis of ASAH1-Related Disorder: Spinal Muscular Atrophy with Progressive Myoclonic Epilepsy (SMA-PME)

Differential Disorder	Gene(s)	MOI	Clinical Features of Differential Disorder
SMN1	AR	Lower MND w/onset age similar to SMA III	Earlier onset of weakness in SMA I II; no seizures or hearing loss in SMA Progressive myoclonus epilepsy, Lafora type
NHLRC1	AR	Progressive myoclonic seizures	No MND in Lafora disease Unverricht-Lundborg disease
CSTB	AR	Progressive myoclonic jerks, tremor	Ataxia lack of MND in Unverricht-Lundborg disease
MERRF	MT-TK1	mt	Myoclonic epilepsy, weakness, hearing loss

Source: GeneReviews — "ASAH1-Related Disorders"

System/Concern	Evaluation	Comment
Constitutional	Assessment for evidence of failure to thrive	—
Respiratory	Airway pulmonary assessment for evidence of pulmonary function due to granulomatous infiltrations	—
Gastrointestinal	Assessment of swallowing, feeding, nutritional status, esp in later stages of disease	—
Musculoskeletal	Referral to specialist in pediatric pain mgmt	Pain due to deforming joint contractures Referral to rehab specialist
Neurologic	Referral to pediatric neurologist	Assess for evidence of lower motor neuron disease or seizure activity.
Hematologic	Assessment for possible hematopoietic stem cell transplantation	For those w/type 2 or 3 FD, as non-CNS symptoms may be improved Miscellaneous/
Other	Consultation w/clinical geneticist or genetic counselor	Referral to palliative care specialist
System/Concern	Evaluation	Comment
Constitutional	Assessment for evidence of poor growth	—
ENT	Audiology eval	Assess for sensorineural hearing loss.
Respiratory	Assessment for pulmonary disease secondary to recurrent aspiration	—
Gastrointestinal	Assessment of feeding nutritional status, esp in later stages of disease	—
Musculoskeletal	Referral to rehab specialist	Evaluate for functional disability in mobility ADL. Assessment for scoliosis
Neurologic	Referral to neurologist	To document extent of any weakness or other neurologic manifestations of SMA-PME to evaluate for evidence of seizures Miscellaneous/
Other	Consultation w/clinical geneticist or genetic counselor	Referral to palliative care specialist
Treatment of Manifestations in Individuals with ASAH1-Related Disorder: Farber Disease Manifestation/Concern	Treatment	Considerations/Other
Aspiration pneumonia	Gastrostomy tube placement	Compromised
airway	Tracheostomy	Consider if airway compromised due to presence of granulomas or for those who are ventilator dependent Surgical removal of granulomas in airway oral cavity
Seizures	Standard ASM as determined by treating neurologist	Cutaneous joint-related
symptoms of FD	Bone marrow transplantation (BMT)	BMT does not alter progression of motor neuron disease or other neurologic manifestations . Hematopoietic stem cell transplantation

Kisho

ASAH1-related sphingolipidosis

Overview

Clinical Presentation

Clinical Guidance

Diagnosis

Diagnostic Criteria

Suggestive Findings

Treatment

Management Guidelines

Prognosis

Surveillance Guidelines

Research Landscape

Recent Publications

Medical References

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

Spinal muscular atrophy with progressive myoclonic epilepsy (SMA-PME)

Differential Diagnosis

Therapies Under Investigation

Clinical Trials

Latest News & Developments

Gene therapy for children with sickle cell disease approved by FDA

ASAH1-related sphingolipidosis

Overview

Clinical Presentation

Clinical Guidance

Diagnosis

Diagnostic Criteria

Suggestive Findings

Treatment

Management Guidelines

Prognosis

Surveillance Guidelines

Research Landscape

Recent Publications

Medical References

Subtypes

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

What is ASAH1-related sphingolipidosis?

What are the symptoms of ASAH1-related sphingolipidosis?

What causes ASAH1-related sphingolipidosis?

How is ASAH1-related sphingolipidosis diagnosed?

Are there treatments for ASAH1-related sphingolipidosis?

What complications can arise from ASAH1-related sphingolipidosis?

How does ASAH1-related sphingolipidosis affect daily life?

What is the life expectancy for someone with ASAH1-related sphingolipidosis?

Should families consider genetic counseling for ASAH1-related sphingolipidosis?

Spinal muscular atrophy with progressive myoclonic epilepsy (SMA-PME)

Differential Diagnosis

Therapies Under Investigation

Clinical Trials

Latest News & Developments

Gene therapy for children with sickle cell disease approved by FDA